Estela Pineda

Publicaciones destacadas

• Mutational profiling allows the stratification of metastatic colorectal cancer patients with poor prognosis

  Autores:

  Rodriguez Hernandez, A; LaHoz, S; Laia, F M; Gorria Puga, T; Moreno, R;

  (...)

  Pineda, E; Castells, A; Prat, A; Camps, J; Maurel, J.

  Ver listado completo de autores

  Referencia: Annals Of Oncology 2023.

• Glioblastoma TCGA mesenchymal and IGS 23 tumors are identifiable by immunohistochemistry and have an immune-phenotype indicating potential benefit from immunotherapy

  Autores:

  Carrato, Cristina; Alameda, Francesc; Esteve-Codina, Anna; Pineda, Estela; Arpi, Oriol;

  (...)

  Fuentes, Rafael; Vidal, Noemi; Aldecoa, Iban; de la Iglesia, Nuria; Balana, Carmen.

  Ver listado completo de autores

  Referencia: Clinical Cancer Research 2020.

• A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond six cycles in patients with glioblastoma (GEINO 14-01)

  Autores:

  Balana C; Vaz MA; Manuel Sepúlveda J; Mesia C; Del Barco S;

  (...)

  Munne N; Domenech M; Villa S; Sanz C; Carrato C .

  Ver listado completo de autores

  Referencia: Neuro-Oncology 2020.

• Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO)

  Autores:

  Manuel Sepulveda-Sanchez, Juan; Gil-Gil, Miguel; Alonso-Garcia, Miriam; Vaz Salgado, Maria Angeles; Vicente, Elena;

  (...)

  Sanchez-Gomez, Pilar; Cruz Martin-Soberon, Maria; Morales-Llombart, Robert; Pachon, Vanessa; Pineda, Estela.

  Ver listado completo de autores

  Referencia: Targeted Oncology 2020.

• Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study

  Autores:

  Rosenthal M; Clement PM; Campone M; Gil-Gil MJ; DeGroot J;

  (...)

  Pineda E; Donnet V; Mills D; El-Hashimy M; Mason W.

  Ver listado completo de autores

  Referencia: Esmo Open 2020.

• MET inhibitors in cancer: pitfalls and challenges

  Autores:

  Oliveres, Helena; Pineda, Estela; Maurel, Joan;

  Referencia: Expert Opinion On Investigational Drugs 2020.

• COULD SUSPECTED GLIOBLASTOMAS BE TREATED WITHOUT HYSTOLOGICAL DIAGNOSIS?

  Autores:

  Cortes Mateus, K; Valduvieco Ruiz, I; Verger Fransoy, E; Pineda Losada, E; Oleaga Zufiria, L;

  (...)

  Camacho Lopez, C; Conill Llobet, C; Oses Gonzalez, G; Garrido Alcantud, S; Molla Armada, M.

  Ver listado completo de autores

  Referencia: Neuro-Oncology 2019.

• LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy

  Autores:

  Pascual-Garcia, Monica; Bonfill-Teixidor, Ester; Planas-Rigol, Ester; Rubio-Perez, Carlota; Ludaro, Raffaella;

  (...)

  Graus, Francesc; EspejoH, Carmen; Sahuquillo, Juan; Tabernero, Josep; Seoane, Joan.

  Ver listado completo de autores

  Referencia: Nature Communications 2019.

• Randomized phase IIb clinical trial of continuation or non-continuation with six cycles of temozolomide after the first six cycles of standard first-line treatment in patients with glioblastoma: A Spanish research group in neuro-oncology (GEINO) trial.

  Autores:

  Balana, Carmen; Mesia Barroso, Carlos; Del Barco Berron, Sonia; Pineda Losada, Estela; Munoz-Langa, Jose;

  (...)

  Perez-Segura, Pedro; Covela Rua, Marta; Carrato, Cristina; Sanz, Carolina; Manuel Sepulveda-Sanchez, Juan;.

  Ver listado completo de autores

  Referencia: Journal Of Clinical Oncology 2019.

• Predictive serum biomarkers in metastatic colorectal cancer patients treated in the BECOX trial with oxaliplatin-capecitabine (CAPOX) plus bevacizumab (GEMCAD 09-01)

  Autores:

  Pineda Losada, E; Salud, A; Vila-Navarro, E; Safont, M J; Garcia-Giron, C;

  (...)

  Bouzas, R; Gironella, M; Garcia-Albeniz, X; Feliu, J; Maurel, J.

  Ver listado completo de autores

  Referencia: European Journal Of Cancer 2015.